Effects of Infusion Timing on Treatment Response in Solid Tumors (NCT07630168)
Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have either advanced or metastatic non-small cell lung cancer (NSCLC) or locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).The study tests the hypothesis that outcomes differ based on infusion timing (morning versus afternoon). Patients are divided into two cohorts by disease type: Cohort 1 includes NSCLC and Cohort 2 includes HNSCC. Within each cohort, patients are randomly assigned to receive infusions in the morning or afternoon, using a 2:1 ratio for NSCLC and a 1:1 ratio for HNSCC. All treatment and disease assessments follow standard medical care, and outcomes such as survival and treatment response are collected from medical records. Patients will be followed for up to 2 years.
Who can join: Review the eligibility criteria below.
Location: University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 984-0000
Email: Adrianna_warner@med.unc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.